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ABSTRACT 
Background and Aims: Psychological morbidity is increased in young people with 
inflammatory bowel disease (IBD).  Illness perceptions may be an important factor. This 
study aimed to describe the prevalence and severity of psychological morbidity and examine 
relationships between baseline illness perceptions and anxiety, depression and health-
related quality of life (HRQoL) at baseline and 12-months later in 16-21-years olds with IBD. 
Methods:  IBD patients (n = 121) completed measures of anxiety, depression, HRQoL, and 
illness perceptions (IPQ-R) at baseline and follow-up (n = 100, 83%).   
Results:  Among the 121 patients at baseline (median age 19.3 years, 40% female, 62% 
Crohn's disease, 73% in clinical remission), 55% reported elevated symptoms of 
anxiety/depression and 83% low HRQoL.  Negative illness perceptions at baseline were 
significantly correlated with greater anxiety, depression and lower HRQoL at baseline and 
follow-up.  In regression analysis at baseline, IPQ-R domain of greater perception of a 
cyclical nature of IBD was an independent predictor of anxiety, whilst a greater perceived 
emotional impact of IBD was an independent predictor of anxiety, depression and HRQoL.  
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Female gender and clinical relapse were also independent predictors of lower HRQoL.  After 
controlling for baseline measures, clinical risk factors and illness perceptions did not explain 
additional variance in psychological morbidity at follow-up.  
Conclusion:  A high prevalence of psychological morbidity, stable over one year, was 
demonstrated in young people with IBD.  Having negative illness perceptions, being female 
and active disease predicted those at greatest risk of psychological morbidity.  Illness 
perceptions may be an appropriate target for psychological interventions. 
Keywords: inflammatory bowel disease, paediatrics, psychological end points  
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1 Introduction 
Inflammatory bowel disease (IBD), including ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ? ?Ănd ulcerative colitis (UC), 
is a chronic relapsing inflammatory disorder of the intestine, increasing in incidence in 
paediatric populations (1 W4), and in particularly in young people (5).  Young people who live 
with IBD face a range of challenges including transitioninŐĨƌŽŵĐŚŝůĚƌĞŶ ?ƐƚŽĂĚƵůƚ services, 
and from parent-led care to self-management whilst at a life stage characterised by change, 
exploration, risk-taking and identity development.  These challenges can represent a major 
psychosocial burden leading to a loss of self-esteem and self-confidence, and heightened 
levels of psychological distress (6).  Young people with IBD have been estimated to be at 
greater than four-fold increased risk of clinically significant symptoms of anxiety or 
depression than healthy peers (7).  A recent study of young people (10-25 years) with IBD 
demonstrated rates of mild anxiety and depressive symptoms in 35%, with severe 
symptoms in 12% (8).  Moreover, a recent systematic review of risk factors and impact of 
IBD in young people with IBD highlighted the wide-ranging impact of psychological 
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morbidity, including abdominal pain, sleep dysfunction, use of psychotropic drugs and non-
adherence to medication (9).     
 
Given the high levels and wide-ranging impact of psychological morbidity in young people 
with IBD, it is important to identify factors that may be targeted in interventions to help 
young people adjust better to living with their condition.  The Common Sense Model of 
Illness (10) proposes that when individuals experience a health threat (i.e. an illness) they 
form cognitive and emotional representations of the health threat, known collectively as 
illness perceptions.  Illness perceptions are an individual ?s beliefs regarding their illness 
across several dimensions (11), and determine their efforts to minimise and/or deal with the 
health threat and, in turn, are related to clinical and psychological outcomes (12,13).  The 
predictive utility of the Common Sense Model and illness perceptions has been 
demonstrated across a diverse range of chronic illness and health behaviours, including non-
adherence to medication (14), depression (15) and mortality (16).  Furthermore, illness 
perceptions are modifiable through psychological interventions (17,18), and these may be 
most effective if delivered early.   
 
In adults with IBD, limited cross-sectional research exists examining the relationship 
between illness perceptions and psychological morbidity and other outcomes (12,19 W23).  
Negative illness perceptions regarding consequences (20,23) and emotional representations 
(19) have been found to correlate with reduced health-related quality of life (HRQoL), 
depression and anxiety (12,21) in addition to lower work productivity (23).  Most recently, in 
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a larger cross-sectional study in adults with IBD, negative illness perceptions regarding 
consequences were associated with lower levels of mental and physical health as well as 
impairment of activity and reduced work activity (22).  In addition, a longitudinal study of 
IBD adult patients found that those with and without arthropathies held significantly 
different illness perceptions (24), suggesting that symptom or disease-related differences 
may impact on illness perceptions and, in turn, psychological morbidity.  To date, there have 
ďĞĞŶŶŽƐƚƵĚŝĞƐĞǆƉůŽƌŝŶŐǇŽƵŶŐƉĞŽƉůĞ ?ƐŝůůŶĞƐƐƉĞƌĐĞƉƚŝŽŶƐĂŶĚƚŚĞŝƌƌĞůĂƚŝŽŶƐŚŝƉǁŝƚŚ
psychological morbidity.   
 
The present study therefore aims to describe the prevalence and severity of psychological 
morbidity (anxiety, depression HRQoL) over a 12-month period in a UK cohort of young 
people aged 16-21 years with IBD.  The study also aims to examine relationships between 
clinical risk factors and illness perceptions, assessed at baseline, and psychological morbidity 
at baseline and 12-month follow-up. 
 
2 Materials and Methods  
2.1 Study design 
Young people aged 16-21 years, with an established diagnosis of IBD (CD, UC or 
Inflammatory Bowel Disease Unspecified (IBDU)) completed measures of psychological 
morbidity (anxiety and depression), HRQoL and illness perceptions.  The World Health 
KƌŐĂŶŝƐĂƚŝŽŶĚĞĮŶĞƐĂĚŽůĞƐĐĞŶĐĞĂƐ the developmental stage between 10 W19 years, and 
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youth as those between 15-24 years.  Together, adolescents and youth are referred to as 
young people.  This study examines young people aged 16-21 years.  
 
The inclusion criteria were (1) age 16-21 years at entry to study and (2) diagnosis of IBD 
defined by current diagnostic criteria (25) for >3 months in order to allow for perceptions 
and ideas about their illness following diagnosis to develop.  Exclusion criteria included any 
patient who was unable to give valid written consent, such as a severe learning disability 
and if unable to speak and read English fluently.  Inclusion and exclusion criteria were 
assessed by the principal investigator (AJB).  All patients gave written consent to participate.  
The study obtained ethics approval from National Research Ethics Service (NRES) Committee 
North East - Sunderland (14/NE/0024).   
 
2.2.  Procedure 
Consecutive patients were recruited between March 2014 and March 2015, with follow-up 
concluded by March 2016.  Patients were recruited from two University hospitals (Sheffield 
dĞĂĐŚŝŶŐ,ŽƐƉŝƚĂůƐE,^&ŽƵŶĚĂƚŝŽŶdƌƵƐƚĂŶĚ^ŚĞĨĨŝĞůĚŚŝůĚƌĞŶ ?Ɛ,ŽƐƉŝƚĂůƐE,^&ŽƵŶĚĂƚŝŽŶ
Trust).  The study was part of a wider research programme examining the experiences of 
young people transitioning from child to adult healthcare.  The two recruitment centres 
participate in a formal transition process for young people with IBD from paediatric to adult 
healthcare with transfer occurring between the ages of 16-18 years.  This involves medical 
and nursing health care professionals attending joint IBD clinics alongside an assessment of 
readiness for transfer in line with current guidelines and international consensus (26,27).   
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Eligible patients were identified by clinical databases held of young people aged 16-21 years 
with IBD within each service and invited to participate by letter (from their usual treating 
consultant) ahead of their scheduled appointment in the IBD service.  At their outpatient 
appointment patients were given the opportunity to enter into the study by a member of 
their healthcare team.  Of 127 patients eligible to participate in the study, 6 (5%) did not 
wish to take part in the study.  Patients were recruited by a member of the research team 
(AJB and AR) following which participants independently completed the questionnaire pack 
on hospital or university premises whilst the researcher was available.  Completed 
questionnaire packs were returned in a sealed envelope to the researcher by the 
participant.  Alternatively, patients could chose to complete the questionnaire pack when 
convenient on paper format and return the questionnaire to a secure university postal 
address.   
 
At 12-month follow-up, patients were approached at scheduled appointments (by AJB, AR 
or EP) or by their chosen preference for follow-up (57% returned follow-up data by post, 
42% at clinic appointment, 1% via email).  If patients failed to respond to the first invitation 
for 12-month follow-up they were sent a reminder by their chosen method.  Two patients 
stated they did not wish to participate at the follow-up time point, a further 19 were lost to 
follow-up during the time period required for completion of the study.  At baseline and at 
12 months, patients completed measures detailed below alongside demographic measures. 
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2.3 Measures 
2.3.1 Demographic characteristics 
Demographic details including age, gender, residential information, educational level, 
ethnicity and employment status were obtained from the patient.  
 
2.3.2 Clinical characteristics   
Clinical information regarding disease classification and severity were collected from 
electronic and paper medical records at baseline, and included Montreal Classification (28), 
current and previous medication and surgical history.  Disease activity was assessed at both 
baseline and follow-up.  For patients with CD this was defined by ƉŚǇƐŝĐŝĂŶ ?ƐŐůŽďĂů
assessment (defined as remission or relapse) and in UC/IBDU by using the criteria of 
Truelove and Witts (defined as remission or relapse; mild, moderate or severe) (29).  C-
reactive protein (CRP) was recorded if obtained in routine clinical care within 90 days of 
recruitment. 
 
2.3.3 Illness Perceptions 
The Illness Perception Questionnaire-Revised (IPQ-R) was used to examine illness 
perceptions.  The IPQ-R is a validated questionnaire that has been used extensively in a wide 
range of chronic conditions (30).  Eight key dimensions were measured: illness identity 
(number of symptoms that patients associate with IBD); time-line chronic (beliefs regarding 
chronicity of IBD); time-line cyclical (perceived variability in the symptoms of IBD); 
consequences (perceived impact of IBD on the patient ?s life); personal control (perceived 
effectiveness of controlling IBD by own behaviour); treatment control (perceived efficacy of 
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IBD treatments); emotional representations (perceived emotional impact of IBD); and illness 
coherence (personal understanding of IBD) (11).   
 
For each dimension, mean scores were computed after recoding inversely formulated items.  
High scores on the illness identity, time-line chronic, consequences, emotional 
representations and time-line cyclical dimensions represent strongly held beliefs about the 
number of symptoms attributed to the illness, the chronicity of the condition, the negative 
consequences of the illness, the greater emotional response to the illness and the cyclical 
nature of the condition.  High scores on the personal control, treatment control and illness 
coherence dimensions represent positive beliefs about the controllability of the illness and a 
personal understanding of the condition.  Internal reliability of the subscales of illness 
perceptions was good ǁŝƚŚƌŽŶďĂĐŚ ?ƐĂůƉŚĂƐƌĂŶŐŝŶŐĨƌŽŵ ? ? ? ?ƉĞƌƐŽŶĂůĐŽŶƚƌů ?ƚŽ ? ? ?
(emotional representations), with the exception of treatment control (.55). 
 
2.3.4 Anxiety and depression  
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS) (31).  Subscale scores were attained by summing the subscale items with higher 
scores indicating a greater severity (subscale range 0 W21) (32).  Both measures of depression 
(alpha = .82) and anxiety (alpha = .85) were found to have a strong internal consistency.  
Severity of anxiety and depression was interpreted according to existing literature as 0 W7 
 “ŶŽƌŵĂů ? ? 8 W ? ? “ŵŝůĚƐĞǀĞƌŝƚǇ ? ? 11 W ? ? “ŵŽĚĞƌĂƚĞƐĞǀĞƌŝƚǇ ? ?ĂŶĚ16 W ? ? “ƐĞǀĞƌĞƐĞǀĞƌŝƚǇ ? 
(31,32). 
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2.3.5 Health-related Quality of Life (HRQoL) 
HRQoL was measured using a disease-specific measure, the IBD Quality of Life 
Questionnaire (IBDQ) (33).  The IBDQ has good psychometric properties (20).  The IBDQ 
contains 32 items rated on 1-7 response scales (range 32-224) in four domains; bowel, 
systemic, social and emotional functioning.  Total scores are used as a measure of HRQoL, 
with a total score >209 taken to indicate HRQoL comparable to that of the general 
population (34).   
 
2.4 Statistical analysis 
Data analyses were performed using Statistical Package for the Social Sciences (IBM Corp 
SPSS Statistics for Windows, Armonk, N.Y., USA).  A power analysis demonstrated 96 
patients to be sufficient to detect a medium effect size of f2=0.21 (R2=.18) in a regression 
analysis with 13 independent variables at 80% power and alpha set at .05.  Descriptive 
statistics were used to characterise IBD patients, measures of illness perceptions as well as 
levels of anxiety, depression and quality of life at baseline and 12-month follow-up.  
Correlations were conducted between the illness perception dimensions and the outcome 
variables (anxiety, depression, and HRQoL), both cross-sectionally (at baseline) and 
prospectively (at follow-up).  Correlations were also conducted between the demographic 
and clinical variables and the outcome variables.  Hierarchical multiple regression analyses 
were conducted to assess the ability of illness perceptions to explain variance in each of the 
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outcome variables, both cross-sectionally and prospectively, after controlling for any 
significant demographic or medical variables.   
 
3 Results 
3.1 Patient Characteristics 
A total of 121 patients completed baseline questionnaires with 31 (26%) and 90 (74%) 
recruited from the paediatric centre and adult centre respectively.  At baseline, the median 
age was 19.33 years (range 16-22.7 years) with 62% of patients diagnosed with CD.  The 
majority (88; 73%) were in clinical remission (CD 56; 78%, UC 22; 56%), with 18 (15%) 
receiving corticosteroids, 78 (64%) on oral immunosuppression, and 43 (36%) receiving anti-
tumour necrosis factor (see Table 1).  No significant changes were found in these clinical 
characteristics between baseline and follow-up.   
 
One hundred patients also completed the follow-up questionnaire at 12 months (attrition at 
follow-up of 17%).  No significant differences were identified between patients who 
completed the follow-up questionnaires compared to those who did not, either in clinical 
(remission vs relapse p= .49, CD vs UC/IBDU p= .99, corticosteroids vs no corticosteroids p= 
.45), or demographic details (employment status p = .24, ethnicity p = .12, gender p = .21, 
age at baseline p = .10, age at diagnosis p = .72, IBD related flares/admission in last year p = 
.74).  Patients who completed the follow-up at 12 months had significantly lower depression 
scores at baseline (M = 3.21, SD = 3.38) compared to those who did not (M = 5.13, SD = 
4.30), t(116) = -2.20, p = .03 (CI -3.64 -1.92).  No other differences were identified in illness 
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perceptions or in the outcome measures of anxiety or HRQoL between patients who 
completed the follow-up compared to those who did not.   
 
Twenty-four (20%) transitioned from paediatric to adult services during the follow-up.  No 
significant differences were found between patients who did or did not transition to adult 
care within the follow-up period for anxiety (M = 6.17, SD = 5.00 vs. M = 6.70, SD = 4.30), 
t(96) = 0.49, p = .63, depression  (M = 3.80, SD = 3.63 vs. M = 3.03, SD = 3.30), t(96) = 0.97, p 
= .34, and HRQoL  (M = 176.64, SD = 40.13 vs. M = 167.49, SD = 34.39), t(95) = 1.07, p = .29, 
at follow-up.  In addition, no significant differences were found between these two groups 
of patients on any of the illness perception measures.  
 
3.2 Prevalence and Severity of Psychological Morbidity over Time 
At baseline, 118 (98%) patients completed the HADS anxiety subscale and HRQoL questions 
and 117 (97%) completed the HADS depression subscale.  Anxiety symptoms were more 
prevalent than depressive symptoms with 24 (20%, CI = 14% to 28%) reporting mild, 17 
(14%, CI = 9% to 22%) moderate and 8 (7%, CI = 3% to 13%) severe symptoms of anxiety 
with the remaining 69 (58%, CI = 49% to 67%) not reporting any anxiety.  Symptoms of 
depression were; 9 (8%, CI = 4% to 14%) reported mild, 6 (5%, CI = 2% to 11%) moderate 
and 1 (1%, CI = 0% to 5%) severe symptoms of depression with the remaining 101 (86%, CI = 
79% to 91%) not reporting any depression.  HRQoL was below the norm for the general 
population in 98 (83%) patients.  
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Between baseline and follow-up at 12 months there were no significant changes in the 
measures of anxiety, depression and HRQoL; baseline anxiety (M = 6.70, SD = 4.49) and 
follow-up anxiety (M = 6.91, SD = 4.49), t(96) = -1.13, p = .26, baseline depression (M = 3.53, 
SD = 3.60) and follow-up depression (M = 3.12, SD = 3.76), t(96) = 0.75, p = .94, and baseline 
HRQoL (M = 167.34, SD = 37.53) and follow-up HRQoL (M = 172.17, SD = 35.08), t(94) = -
0.34, p = .73.    
 
3.3 Associations between Demographic/Clinical Risk Factors and 
Psychological Morbidity 
Gender and disease activity affected psychological morbidity at baseline.  Females reported 
significantly higher anxiety than males (p = .006) as well as lower HRQoL (p = .0005).  Higher 
depression scores were associated with clinical relapse versus remission (p = .006), and 
corticosteroid use versus no corticosteroids (p = .004).  Poorer HRQoL was associated with 
an older age at diagnosis of IBD (p = .010), older patients (p = .007), clinical relapse versus 
clinical remission (p < .001), and corticosteroid use versus no corticosteroids (p = 0.039) (see 
Supplementary Data; Table 1).  At follow-up, significantly higher levels of depressive 
symptoms were observed in those in clinical relapse versus remission at baseline (p = .022).  
Similarly, lower HRQoL scores at follow-up was found for those in clinical relapse versus 
remission at baseline (p = .022).  Significantly lower HRQoL scores at follow-up were also 
observed among those with a diagnosis of UC versus CD at baseline (p = .026), and older age 
at diagnosis (p = .021) (see Supplementary Data; Table 2).  Other clinical variables (i.e., 
receiving biologic therapy, oral immunomodulators or previous surgical resections) were 
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found to have non-significant associations with psychological morbidity at baseline and 
follow-up.  
 
3.4 Associations between Demographic/Clinical Risk Factors and Illness 
Perceptions 
Gender affected illness perceptions, with more negative illness perceptions in female 
patients compared to males in relation to time-line cyclical, time-line chronic, treatment 
control, illness coherence and emotional representations (see Supplementary Data; Table 
3).  Patients defined as having active disease compared to those in remission had a greater 
perceived emotional impact of IBD (emotional representations) compared to those in 
remission (p = .04), and lower perception of effectiveness of controlling IBD by own 
behaviour (personal control) (p = .001) (see Supplementary Data; Table 3). 
 
3.5 Associations between Illness Perceptions and Psychological Morbidity 
At baseline, all illness perceptions dimensions, with the exception of the perception of a 
chronic time-line, had significant correlations with psychological morbidity (anxiety, 
depression and HRQoL) (see Table 2).  Prospective correlations were conducted to 
investigate the relationship between baseline illness perceptions and follow-up 
psychological morbidity (see Table 2).  Perceived negative consequences of IBD 
(consequences) and a greater emotional response to IBD (emotional representations) at 
baseline correlated with follow-up anxiety, depression and HRQoL. In addition, treatment 
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control at baseline correlated with follow-up depression and HRQoL, and personal control at 
baseline correlated with follow-up HRQoL. 
 
3.5 Regression Analyses Identifying Predictors of Psychological Morbidity  
Female gender explained 5% of the variance of anxiety at baseline when entered into the 
first block of the hierarchical regression analysis, R
2
 = .05, F(1,112) = 5.68, p = .02.  The 
inclusion of illness perceptions explained an additional 44% of the variance ?A?R2 = .44, 
F(6,106) = 15.20, p < .001.  The variables in the final regression equation explained 49% of 
the variance in baseline anxiety, R
2
 = .49, F(7,106) = 14.45, p < .001.  A greater emotional 
response to IBD (emotional representations) and a greater perception of a cyclical nature of 
IBD (time-line cyclical) made significant independent contributions to the final regression 
model (see Table 3).   
 
Clinical relapse and corticosteroid use explained 8% of the variance in depression at baseline 
when entered into the first block of the hierarchical regression analysis, R
2
 = .08, F(2,111) = 
4.81, p = .01; only clinical relapse made a significant independent contribution to the 
regression model.  The inclusion of illness perceptions explained an additional 24% of the 
variance in depression, A?R2 = .24, F(7,104) = 5.33, p < .001.  The variables in the final 
regression equation explained 32% of the variance in baseline depression, R
2
 = .32, F(9,104) 
= 5.50, p < .001, with only a greater emotional response to IBD (emotional representations) 
identified as a significant independent predictor (see Table 4).   
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A number of clinical variables (gender, age at diagnosis, clinical relapse, and corticosteroid 
use) explained 35% of the variance of HRQoL at baseline when entered into the first block of 
the hierarchical regression analysis, R
2
 = .35, F(4,109) = 14.68, p < .001, although only 
gender and clinical relapse made significant contributions to the regression model.  The 
inclusion of illness pĞƌĐĞƉƚŝŽŶƐĞǆƉůĂŝŶĞĚĂŶĂĚĚŝƚŝŽŶĂů ? ?A?ŽĨƚŚĞǀĂƌŝĂŶĐĞŽŶ,ZYŽ> ?A? R2 = 
.25, F(7,102) = 9.04, p < .001.  The variables in the final regression equation explained 60% 
of the variance of baseline HRQoL, R
2
 = .60, F(11,102) = 13.84, p < .001.  Female gender, 
clinical relapse and a greater emotional response to IBD (emotional representations) made 
significant independent contributions to the final regression model (see Table 5).  
 
Examining the predictors of psychological morbidity and quality of life at follow-up while 
controlling for baseline anxiety, depression and HRQoL, revealed that baseline 
demographics, clinical variables and illness perceptions were unable to explain any 
additional variance in psychological morbidity and quality of life at follow-up 
(Supplementary Data; Tables 4-6). 
 
4 Discussion 
The current study of young people aged 16-21 years with IBD demonstrated high rates of 
anxiety/depressive symptoms, with a combined prevalence of (55%).  This is greater than 
the most recently published data in patients between the ages of 10 and 25 years with IBD 
(47%) (8), and is markedly higher than national UK statistics (19%) reported for 16-24 year 
olds (35).  Of particular concern are high rates of anxiety reported in 42%, compared to 19% 
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rate reported in a recent systematic review for adults with IBD (36), and 28% in 10-25 year 
olds with IBD (8).  The rate of depressive symptoms observed in the current sample was 
13%, lower than the 21% rate that has been reported for adults with IBD (36, 38), but much 
greater than 3% observed in van den Brink data (8).  Furthermore, our data show low HRQoL 
in young people aged 16-21 years with IBD, with 83% scoring lower than that of the general 
population.  
 
The major finding of this study is the impact of illness perceptions on psychological 
morbidity. With the exception of the perception of a chronic time-line, all illness perceptions 
were significantly correlated with psychological morbidity at baseline. In the regression 
analyses, illness perceptions were able to explain large amounts of variance in anxiety, 
depression, and HRQoL at baseline, whilst controlling for demographic and clinical variables.  
In particular, emotional representations (i.e., greater perception of the emotional impact of 
IBD) was an independent predictor of all measures of psychological morbidity and quality of 
life at baseline.  These data support findings in adult IBD cohorts of illness perceptions (22), 
but are demonstrated for the first time in a young adult cohort.   Prospectively, a greater 
perception of the emotional impact of IBD as well as the perceived impact of IBD on 
ƉĂƚŝĞŶƚƐ ?ůŝĨĞ at baseline were correlated with increased anxiety and depression and lower 
HRQoL at follow-up.  Greater positive beliefs about personal control (perceived 
effectiveness of controlling IBD through own behaviour) and the perceived efficacy of IBD 
treatments at baseline were also correlated with higher HRQoL at follow-up.  In addition, 
lower perceived efficacy of IBD treatments at baseline correlated with increased depression 
at follow-up.  However, despite these significant correlations, illness perceptions were 
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unable to explain additional variance in psychological morbidity and quality of life at follow-
up after controlling for baseline morbidity. This may have been due to the lack of change in 
anxiety, depression and quality of life between baseline and follow-up.   
 
Illness perceptions varied according to disease activity, with a greater perceived emotional 
impact of IBD observed in disease relapse, and a lower perception of the effectiveness of 
controlling IBD ƚŚƌŽƵŐŚƉĂƚŝĞŶƚƐ ? own behaviour compared to those in remission.  
Regression analyses identified clinical relapse and female gender as independent predictors 
of lower HRQoL at baseline. These findings are in line with previous research indicating a 
strong relationship between physical disease and psychological morbidity (13,37 W39), and 
the relationship has important clinical implications, s disease control is vital for physical 
and mental health.  Furthermore, the gender differences observed are in line with studies 
demonstrating adverse mental health outcomes in general population females in this age 
group (35,40), including suicide surpassing maternal mortality as the leading, global cause of 
death among girls aged 15-19 years (41).  Other IBD studies in adults, children and young 
people have also demonstrated gender differences, with female patients reporting greater 
self-report concerns (e.g. socialisation and stigmatization, constraints and uncertainty and 
loss of body control) compared to men, associated with anxiety (8,42).  Furthermore, HRQoL 
was significantly lower in patients with UC compared to CD at follow-up.  This finding is in 
contrast to other research which has reported no differences in HRQoL between UC and CD 
(43,44).  This may be explained by the significantly greater proportion of UC patients in 
clinical relapse in the current sample.   
 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/e
c
c
o
-jc
c
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/e
c
c
o
-jc
c
/jjz
0
2
8
/5
3
0
6
9
6
4
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 0
5
 M
a
rc
h
 2
0
1
9
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz028 
 
Our data support European and American consensus IBD guidelines stating screening is 
required for depression and anxiety alongside access to psychologists as part of standard 
IBD services (45 W47).  Despite this, access to a defined psychologist with an interest in IBD 
remains low at 12% in adult IBD services in the United Kingdom (48), in contrast to defined 
access to a psychologist in 67% of paediatric gastroenterology centres (49).  The current 
reactive, rather than preventative, approach to psychological well-being in care of adults 
with IBD (50) is likely to have a negative consequence on self-management behaviours such 
as adherence, health risk behaviours and subsequent personal and societal cost through 
work impairment (22), with young people at the greatest risk (40).  A prior Cochrane review 
suggested that psychological interventions in IBD may of particular benefit in adolescents 
(51).  Evidence regarding the impact of psychological therapies in IBD patients (>16 years) 
suggests current therapies (in particular cognitive behavioural therapy), may have small 
short-term beneficial effects on depression scores (52).  However, in other chronic diseases 
evidence regarding interventions based on the Common Sense Model through targeting 
illness perceptions demonstrate that these are modifiable through psychological 
interventions (17), and may be most effective if delivered early.  For example in asthma, 
self-report adherence to preventative medication improved with a targeted text message 
ƉƌŽŐƌĂŵŵĞƵƐŝŶŐƚĂŝůŽƌĞĚŵĞƐƐĂŐĞƐďĂƐĞĚŽŶĂŶŝŶĚŝǀŝĚƵĂů ?ƐŝůůŶĞƐƐƉĞƌĐĞƉƚŝŽŶƐ (17).  In IBD  
very limited data exists regarding psychological interventions, with one study having 
demonstrated an improvement in adjustment to IBD (17,53,54).  Importantly, the current 
study has demonstrated that psychological interventions based on illness perceptions 
should focus on the perceived emotional impact of IBD (emotional representation).   
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The study had important limitations.  First, self-report measures were used to assess 
psychological morbidity, which may be subject to bias.  Future studies should consider 
incorporating a qualified clinician-based diagnostic-interview for confirmation of anxiety and 
depression (50).  Second, disease activity was found to have a negative relationship with 
illness perceptions and psychological morbidity and, as a result, achieving remission for 
young people with IBD may be central to improving their psychological wellbeing.  Objective 
methods of disease activity assessment (e.g., faecal calprotectin) or endoscopic assessment 
of disease activity would strengthen the study findings and should be considered in future 
studies (50).  Limited longitudinal data exists in IBD to determine the impact of disease 
activity over time on psychological morbidity (55) and, in our cohort, no significant changes 
in clinical disease activity over 12-month follow-up were observed.  Third, like most studies 
in this area the sample was predominantly Caucasian; therefore the role ethnicity may play 
in psychological morbidity and illness perceptions remains uncertain (9).  Fourth, our 
recruitment sites included a paediatric centre with a formal transition process for young 
people with IBD moving to adult healthcare.  We did not demonstrate higher rates of 
psychological morbidity in those who had undergone transition ĨƌŽŵĐŚŝůĚƌĞŶ ?ƐƚŽĂĚƵůƚ
healthcare compared to those who did not.  However, future studies should consider 
psychological morbidity where formal transition arrangements do not exist.  Inadequate 
transition processes are associated with clinic non-attendance and non-adherence with 
medication, restricted growth potential and an increased likelihood of requiring surgery 
(56), but the impact on psychological morbidity is unknown.  Finally, future studies in this 
area must consider engagement of participants irrespective of mental health status.  We 
demonstrated that patients with higher depression scores at baseline were less likely to 
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complete follow-up assessment and they may also be less likely to engage with healthcare 
services.   
 
In conclusion, the high rates of psychological morbidity observed in the current study 
warrant a systematic approach to screening for psychological morbidity in young people 
with IBD.  Illness perceptions play an important role in psychological morbidity in this age 
group with a greater perception of the emotional impact of IBD (emotional representation) 
an independent predictor of all measures of psychological morbidity.  Early identification 
and targeted interventions of negative illness perceptions may be crucial in altering key self-
management behaviours and health-related outcomes in young people with IBD, and should 
be a priority for future research and development of targeted psychological interventions.  
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TABLE 1 Demographic and clinical characteristics of patients at baseline  
    
 Factor  N  n (%) 
Gender  121 
 Male 
 
60 (49.6) 
Race  120 
 Caucasian  
 
104 (87) 
Other  
 
16 (13) 
IBD Type  121 
 CD 
 
75 (62) 
UC 
 
39 (32.2) 
IBDU 
 
7 (5.8) 
Age at diagnosis (years) 121 14.05 ± 3.44) 
Disease duration (months) 121 45 [3-160] 
Montreal location at diagnosis  75 
      L1 
 
11 (14.7) 
     L2 
 
14 (18.7) 
     L3 
 
48 (64) 
     Isolated upper GI 
 
2 (2.7) 
Montreal behaviour at diagnosis 75 
     B1 
 
31 (41.3) 
    B2 
 
19 (25.3) 
    B3 
 
3 (4) 
    B1/B2 or B3 & p 
 
8 (10.6) 
    Perianal 
 
14 (18.7) 
Montreal classification of extent (UC/IBDU) 44 
     E1 
 
4 (8.7) 
    E2 
 
18 (39.1) 
    E3 
 
22 (47.8) 
Disease Severity  121 
     Clinically active disease  
 
33 (27.3) 
CRP 59 6.2 (10.6) 
Current smoker  
 
15 (13) 
Biologic therapy  121 43 (35.5) 
Immunosuppressive medication 121 
     Thiopurine  
 
69 (57) 
    Methotrexate 
 
7 (5.8) 
    Ciclosporin 
 
2 (1.7) 
Corticosteroid  
 
18 (14.9) 
Surgery  39 
      Abdominal surgery  
 
25 (20.7) 
     Current stoma  
 
6 (5) 
     Past stoma    8 (6.6)  
Statistics presented as M ± SD, median [range] or N (column %). 
 ?ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?h ?ƵůĐĞƌĂƚŝǀĞĐŽůŝƚŝƐ ?/h ?ŝŶĨůĂŵŵĂƚŽƌǇďŽǁĞů  disease unclassified  
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/e
c
c
o
-jc
c
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/e
c
c
o
-jc
c
/jjz
0
2
8
/5
3
0
6
9
6
4
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 0
5
 M
a
rc
h
 2
0
1
9
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz028 
 
 
 
Note: * p < .05. **p < .01 
 
 
 
 
 
 
 
 
  
TABLE 2 Correlation of Illness Perceptions with Baseline and Follow-up Psychological Morbidity    
    Baseline      Follow-up   
Dimensions Anxiety  Depression IBDQ   Anxiety Depression IBDQ  
Illness identity   .35**  .39** -.42**  .12  .20 -.16 
Time-line chronic -.01 -.11 -.16  .06  .04 -.07 
Consequences  .53**  .44** -.50**  .38**  .37** -.35** 
Personal control  -.18 -.25** . 32** -.17 -.19  .24* 
Treatment control  -.22* -.28**  .34** -.13 -.21*  .25* 
Illness coherence  -.30** -.22*  .37** -.14 -.09  .16 
Time-line cyclical   .49**  .25** -.45**  .20  .05 -.12 
Emotional representations   .66**  .49** -.60**  .43**  .38** -.36** 
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TABLE 3 Summary of Hierarchical Regression Analyses Predicting Baseline Anxiety (N = 121) 
 
Step Variable    B SE B  ɴ  95% CIs 
Step 1 Gender   1.93 0.81  0.22*  0.33 to 3.54 
Step 2 Gender  -0.15 0.71 -0.02  1.55 to 1.25 
 
Illness identity   0.07 0.14  0.05 -0.20 to 0.34 
 
Consequences  0.06 0.63  0.01 -1.19 to 1.32 
 
Treatment control  -0.42 0.63 -0.05 -1.66 to 0.82 
 
Illness coherence   0.53 0.44  0.10 -0.34 to 1.40 
 
Time-line cyclical   1.18 0.44  0.25**  0.32 to 2.05 
  Emotional Representations   2.20 0.43  0.56***  1.34 to 3.05 
Note. Step 1 R
2
 = 0.05, p = 0.02.  Step 2 R
2
 = 0.49, p < 0.001. * p <0 .05. **p < 0.01. *** p < 0.001 
 
 
 
 
 
 
 
 
TABLE 4 Summary of Hierarchical Regression Analyses Predicting Baseline Depression (N =121) 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step Variable    B    SE B ɴ 95% CIs 
Step 1 Clinical relapse   2.01 0.85  0.25*  0.32 to 3.69 
 
Current steroids  0.60 1.04  0.06 -1.45 to 2.66 
Step 2 Clinical relapse   1.04 0.80  0.13 -0.55 to 2.64 
 
Current steroids  0.93 0.94  0.09 -0.94 to 2.79 
 
Illness identity   0.13 0.13  0.11 -0.13 to 0.39 
 
Consequences  0.59 0.60  0.13 -0.60 to 1.78 
 
Personal control  -0.11 0.53 -0.02 -1.15 to 0.94 
 
Treatment control  -0.89 0.60 -0.14 -2.08 to 0.31 
 
Illness coherence   0.26 0.42  0.06 -0.58 to 1.10 
 
Time-line cyclical  -0.08 0.39 -0.02 -0.85 to 0.69 
  Emotional Representations   1.02 0.42  0.31*  0.18 to 1.85 
Note. Step 1 R
2
 = 0.08, p = 0.10.  Step 2 R
2
 = 0.32, p < 0.001. * p < 0.05 
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TABLE 5 Summary of Hierarchical Regression Analyses Predicting Baseline HRQoL (N = 121) 
 
Step Variable    B    SE B ɴ 95% CIs 
Step 1 Gender -28.49 5.88 -0.38*** -40.15 to -16.83 
 
Age at diagnosis (years) -1.03 0.90 -0.09   2.82 to 0.77 
 
Clinical relapse  -40.84 7.75 -0.48*** -56.19 to -25.49 
 
Current steroids   1.35 9.16  0.01 -16.81 to 19.51 
Step 2 Gender -13.68 5.49 -0.18* -24.57 to 2.79 
 
Age at diagnosis (years) -0.37 0.77 -0.03 -1.90 to 1.15 
 
Clinical relapse  -30.18 6.77 -0.36*** -43.61 to 16.75 
 
Current steroids   0.92 7.58  0.01   14.18 to 15.96 
 
Illness identity  -1.81 1.03 -0.15   3.86 to 0.23 
 
Consequences -5.27 4.93 -0.11   15.05 to 4.50 
 
Personal control    2.19 4.24   0.04 -6.21 to 10.60 
 
Treatment control    7.31 4.82   0.11 -2.25 to -16.87 
 
Illness coherence    0.94 3.34   0.02 -5.68 to 7.55 
 
Time-line cyclical -5.11 3.12 -0.13 -11.29 to 1.08 
  Emotional Representations  -7.93 3.44 -0.23* -14.75 to -1.10 
Note. Step 1 R
2
 = 0.35, p < 0.001.   
Step 2 R
2
 = 0.599, p < 0.001. * p < 0.05. **p < 0.01. *** p < 0.001 
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